152 related articles for article (PubMed ID: 25675131)
1. TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.
Guiho R; Biteau K; Heymann D; Redini F
Future Oncol; 2015; 11(3):535-42. PubMed ID: 25675131
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
3. Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcoma and myeloma cells.
Suzuki H; Hotta T; Koyama T; Komagata M; Imakiire A; Yanase N; Yoshimoto T; Mizuguchi J
Anticancer Res; 2003; 23(4):3247-53. PubMed ID: 12926060
[TBL] [Abstract][Full Text] [Related]
4. TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma.
Phillips KL; Wright N; McDermott E; Cross NA
Biochem Biophys Res Commun; 2019 Sep; 517(2):383-389. PubMed ID: 31362889
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
Lissat A; Vraetz T; Tsokos M; Klein R; Braun M; Koutelia N; Fisch P; Romero ME; Long L; Noellke P; Mackall CL; Niemeyer CM; Kontny U
Am J Pathol; 2007 Jun; 170(6):1917-30. PubMed ID: 17525260
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
7. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
8. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.
Gamie Z; Kapriniotis K; Papanikolaou D; Haagensen E; Da Conceicao Ribeiro R; Dalgarno K; Krippner-Heidenreich A; Gerrand C; Tsiridis E; Rankin KS
Cancer Lett; 2017 Nov; 409():66-80. PubMed ID: 28888998
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Ca2+ removal amplifies TRAIL cytotoxicity toward apoptosis-resistant tumor cells via promotion of multiple cell death modalities.
Takata N; Ohshima Y; Suzuki-Karasaki M; Yoshida Y; Tokuhashi Y; Suzuki-Karasaki Y
Int J Oncol; 2017 Jul; 51(1):193-203. PubMed ID: 28560396
[TBL] [Abstract][Full Text] [Related]
10. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM
Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
13. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Pal S; Shankar BS; Sainis KB
Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
[TBL] [Abstract][Full Text] [Related]
14. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
[TBL] [Abstract][Full Text] [Related]
15. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
16. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
[TBL] [Abstract][Full Text] [Related]
17. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
18. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
Goda AE; Yoshida T; Horinaka M; Yasuda T; Shiraishi T; Wakada M; Sakai T
Oncogene; 2008 May; 27(24):3435-45. PubMed ID: 18193086
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.
Grisendi G; Spano C; D'souza N; Rasini V; Veronesi E; Prapa M; Petrachi T; Piccinno S; Rossignoli F; Burns JS; Fiorcari S; Granchi D; Baldini N; Horwitz EM; Guarneri V; Conte P; Paolucci P; Dominici M
Stem Cells; 2015 Mar; 33(3):859-69. PubMed ID: 25420617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]